Combined Measurement of the Higgs Boson Mass in pp Collisions at sqrt[s]=7 and 8 TeV with the ATLAS and CMS Experiments.

Overview

The Federal Drug Administration (FDA) has approved several new medications for the treatment of obesity in the past five years. Using pharmacotherapy for weight management is consistent with treating obesity as a chronic disease that requires a multifaceted approach including behavioral intervention, dietary change, and appropriate medical intervention. Current guidelines recommend that individuals who fail to respond to lifestyle interventions after 6 months of treatment, and have a BMI of > 30 kg/m² or a BMI of > 27 kg/m² with an obesity-related comorbidity may be considered for weight loss medication treatment. The anti-obesity medications reviewed in this chapter include the FDA-approved medicines for chronic weight management, FDA-approved medicines for short-term use of weight management, and off-label use of medicines for weight control.